CG
VVOS icon

Cutler Group’s Vivos Therapeutics VVOS Stock Holding History

Cutler Group’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-12
Closed – – 3758
2023
Q4 		$0 Sell
12
-232
-95% -$1.99K ﹤0.01% 4425
2023
Q3 		$1K Hold
244
– – ﹤0.01% 3676
2023
Q2 		$3K Hold
244
– – ﹤0.01% 2926
2023
Q1 		$2K Buy
+244
New +$5.34K ﹤0.01% 3273
2021
Q4 		– Sell
-20
Closed -$1.61K – 6167
2021
Q3 		$2K Buy
+20
New +$2.1K ﹤0.01% 5124

Other funds holding VVOS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $6.53B AUM 20.48% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cutler Group's VVOS Position: Q1 2024 in Review

Cutler Group sold out of Vivos Therapeutics (VVOS) in Q1 2024, closing a stake of 12 shares.

Cutler Group first reported a position in VVOS in Q3 2021 and held it in 5 quarters. The position peaked at $3K in Q2 2023. 16 funds tracked by Wall St. Rank hold VVOS as of Q1 2024.

  • Cutler Group reported no remaining Vivos Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 12 Vivos Therapeutics shares in Q1 2024.
  • Cutler Group first reported a position in Vivos Therapeutics in Q3 2021 and held it in 5 quarters.
  • Cutler Group's Vivos Therapeutics position peaked at $3K in Q2 2023.
  • 16 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.